Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe traditional immunotherapeutic approaches to treating advanced renal cell carcinoma (RCC)
- Review novel therapeutic agents that target various molecular features characteristic of RCC
- Discuss the evolution of treatment strategies for RCC, including the combination of targeted agents with standard therapies
Topics covered include:
- Introduction
- Understanding Advanced RCC: Rethinking Standard Approaches to Treatment
- Epidemiology of Renal Cell Carcinoma
- Cytoreductive Nephrectomy
- Cytokine Therapy for Advanced RCC
- Risk Stratification
- Novel Agents: Unique Therapeutic Targets in Advanced RCC
- Molecular Biology of RCC: VHL and VEGF
- Bevacizumab in RCC
- Sunitinib in RCC
- Sorafenib in RCC
- What's Next? Emerging Data in RCC
- Adjuvant and Neoadjuvant Treatments
- Frontline/Monotherapy Treatment of Metastatic RCC
- Defining the Relationship Between IL-2 Treatment and CA IX
- Overcoming TKI Resistance
- Combinations of Novel Agents
- Conclusion